Table 1.
Characteristics of patients that participated in the study and received a microdose or microtracer [14C]midazolam. Data are presented as median (range)
| Total | Microdose | Microtracer | Mann–Whitney U microdose vs microtracer group (P‐value) | |
|---|---|---|---|---|
| Number of patients | 15 | 9 | 6 | ‐ |
| Number of samples | 67 | 37 | 30 | ‐ |
| Samples per patient (n) | 5 (2–5) | 5 (2–5) | 5 (5–5) | ‐ |
| Gestational age (wk) | 39.4 (23.9–41.4) | 39.4 (23.9–41.4) | 38.4 (26.7–41.0) | .15 |
| Postnatal age (weeks) | 11.4 (0.6–49.1) | 11.4 (0.6–49.1) | 13.4 (2.6–42.3) | .39 |
| Weight (kg) | 3.6 (2.6–8.9) | 3.5 (2.7–8.9) | 3.8 (2.6–6.0) | 1.00 |
| Plasma creatinine (μmol L−1) | 35 (20–51) | 41 (29–51) | 33 (20–36) | .07 |
| Total bilirubin (μmol L−1) | 9 (2–274) | 9 (5–274) | 9 (2–146) | .46 |
| ASAT (U L−1) | 42 (12–93) | 41 (12–93) | 57 (25–85) | .39 |
| ALAT (U L−1) | 17 (7–68) | 15 (7–43) | 23 (16–68) | .09 |